FAU.de
Deutsch
Login
Home
Publications
Research Grants
Inventions & Patents
Awards
Additional Research Activities
Faculties & Institutions
Research Areas
Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss
Hospital
Location:
Neuss, Germany (DE)
ISNI
: -
Publications
(9)
Types of publications
Toggle all
Journal article
Journal article
Book chapter / Article in edited volumes
Book chapter / Article in edited volumes
Authored book
Authored book
Translation
Translation
Thesis
Thesis
Edited Volume
Edited Volume
Conference contribution
Conference contribution
Other publication type
Other publication type
Unpublished / Preprint
Unpublished / Preprint
Publication year
From
To
Abstract
Journal
Filters (inactive)
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy (2022)
Leichsenring J, Vladimirova V, Solbach C, Karn T, Ataseven B, Sinn BV, Barinoff J, et al.
Journal article
Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC) (2022)
Reinisch M, Blohmer JU, Link T, Just M, Untch M, Stoetzer O, Fasching P, et al.
Conference contribution
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients with Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial (2022)
Blohmer JU, Link T, Reinisch M, Just M, Untch M, Stotzer O, Fasching P, et al.
Journal article
GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status (2020)
Link T, Blohmer JU, Just M, Untch M, Stoetzer O, Fasching P, Schneeweiss A, et al.
Conference contribution
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial (2019)
Schneeweiss A, Moebus V, Tesch H, Hanusch C, Denkert C, Luebbe K, Huober J, et al.
Journal article
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy (2018)
Denkert C, Von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, et al.
Journal article
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2017)
Kuemmel S, Paepke S, Huober J, Schem C, Untch M, Blohmer JU, Eiermann W, et al.
Journal article
Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE) (2016)
Paepke S, Huober J, Sherko K, Eidtmann H, Untch M, Costa SD, Blohmer JU, et al.
Conference contribution
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy (2015)
Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching P, Pfitzner BM, Gerber B, et al.
Journal article